Last reviewed · How we verify
SV001
At a glance
| Generic name | SV001 |
|---|---|
| Sponsor | Shanghai Synvida Biotechnology Co.,Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of SV001 in Chinese Healthy Adult Volunteers. (EARLY_PHASE1)
- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SV001 CI brief — competitive landscape report
- SV001 updates RSS · CI watch RSS
- Shanghai Synvida Biotechnology Co.,Ltd. portfolio CI